Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model

Daptomycin (DAP) is being used more frequently to treat infections caused by vancomycin-resistant enterococcus (VRE). DAP tends to be less active against enterococci than staphylococci and may require high doses or combination therapy to be bactericidal. Fosfomycin (FOF) has activity against VRE and...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Antimicrob Agents Chemother
Egile Nagusiak: Hall Snyder, Ashley D., Werth, Brian J., Nonejuie, Poochit, McRoberts, John P., Pogliano, Joe, Sakoulas, George, Yim, Juwon, Singh, Nivedita, Rybak, Michael J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Microbiology 2016
Gaiak:
Experimental Therapeutics
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5038233/
https://ncbi.nlm.nih.gov/pubmed/27431211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00687-16
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak